132 related articles for article (PubMed ID: 32716238)
1. Re: Lymphovascular Invasion and Presence of Embryonal Carcinoma as Risk Factors for Occult Metastatic Disease in Clinical Stage I Nonseminomatous Germ Cell Tumour: A Systematic Review and Meta-Analysis.
Richie JP
J Urol; 2020 Oct; 204(4):881. PubMed ID: 32716238
[No Abstract] [Full Text] [Related]
2. Lymphovascular invasion and presence of embryonal carcinoma as risk factors for occult metastatic disease in clinical stage I nonseminomatous germ cell tumour: a systematic review and meta-analysis.
Blok JM; Pluim I; Daugaard G; Wagner T; Jóźwiak K; Wilthagen EA; Looijenga LHJ; Meijer RP; Bosch JLHR; Horenblas S
BJU Int; 2020 Mar; 125(3):355-368. PubMed ID: 31797520
[TBL] [Abstract][Full Text] [Related]
3. Risk stratification of pubertal children and postpubertal adolescents with clinical stage I testicular nonseminomatous germ cell tumors.
Cost NG; Lubahn JD; Adibi M; Romman A; Wickiser JE; Raj GV; Sagalowsky AI; Margulis V
J Urol; 2014 May; 191(5 Suppl):1485-90. PubMed ID: 24679874
[TBL] [Abstract][Full Text] [Related]
4. Microvascular invasion of testicular nonseminomatous germ cell tumors: implications of separate evaluation of lymphatic and blood vessels.
Heinzelbecker J; Gross-Weege M; Weiss C; Hörner C; Trunk MJ; Erben P; Haecker A; Bolenz C
J Urol; 2014 Aug; 192(2):593-9. PubMed ID: 24631105
[TBL] [Abstract][Full Text] [Related]
5. Predictors of positive retroperitoneal lymph nodes in patients with high risk testicular cancer.
Williams SB; Kacker R; Winston D; Bahnson E; Steele GS; Richie JP
J Urol; 2011 Dec; 186(6):2245-8. PubMed ID: 22014805
[TBL] [Abstract][Full Text] [Related]
6. Percentage of embryonal carcinoma and of vascular invasion predicts pathological stage in clinical stage I nonseminomatous testicular cancer.
Moul JW; McCarthy WF; Fernandez EB; Sesterhenn IA
Cancer Res; 1994 Jan; 54(2):362-4. PubMed ID: 8275469
[TBL] [Abstract][Full Text] [Related]
7. Flow cytometric and quantitative histological parameters to predict occult disease in clinical stage I nonseminomatous testicular germ cell tumors.
Moul JW; Foley JP; Hitchcock CL; McCarthy WF; Sesterhenn IA; Becker RL; Griffin JL
J Urol; 1993 Sep; 150(3):879-83. PubMed ID: 8393944
[TBL] [Abstract][Full Text] [Related]
8. alpha-Catenin expression pattern and DNA image-analysis cytometry have no additional value over primary histology in clinical stage I nonseminomatous testicular cancer.
Spermon JR; De Wilde PC; Hanselaar AG; Schaafsma HE; Ruijter TE; Witjes JA; Van Moorselaar RJ
BJU Int; 2002 Feb; 89(3):278-84. PubMed ID: 11856111
[TBL] [Abstract][Full Text] [Related]
9. Proliferating cell nuclear antigen expression to predict occult disease in clinical stage I nonseminomatous testicular germ cell tumors.
Fernandez EB; Sesterhenn IA; McCarthy WF; Mostofi FK; Moul JW
J Urol; 1994 Oct; 152(4):1133-8. PubMed ID: 7915335
[TBL] [Abstract][Full Text] [Related]
10. Management of clinical stage I nonseminomatous germ cell testicular cancer.
Choueiri TK; Stephenson AJ; Gilligan T; Klein EA
Urol Clin North Am; 2007 May; 34(2):137-48; abstract viii. PubMed ID: 17484919
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of surveillance protocol of clinical stage I nonseminomatous germ cell tumors-is shift to risk adapted policy justified?
Divrik RT; Akdoğan B; Ozen H; Zorlu F
J Urol; 2006 Oct; 176(4 Pt 1):1424-29; discussion 1429-30. PubMed ID: 16952649
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical expression of P53 tumor suppressor gene protein in adult germ cell testis tumors: clinical correlation in stage I disease.
Lewis DJ; Sesterhenn IA; McCarthy WF; Moul JW
J Urol; 1994 Aug; 152(2 Pt 1):418-23. PubMed ID: 8015085
[TBL] [Abstract][Full Text] [Related]
13. A refined risk stratification scheme for clinical stage 1 NSGCT based on evaluation of both embryonal predominance and lymphovascular invasion.
Lago-Hernandez CA; Feldman H; O'Donnell E; Mahal BA; Perez V; Howard S; Rosenthal M; Cheng SC; Nguyen PL; Beard C; D'Amico AV; Sweeney CJ
Ann Oncol; 2015 Jul; 26(7):1396-401. PubMed ID: 25888612
[TBL] [Abstract][Full Text] [Related]
14. Association of intratubular seminoma and intratubular embryonal carcinoma with invasive testicular germ cell tumors.
Lau SK; Weiss LM; Chu PG
Am J Surg Pathol; 2007 Jul; 31(7):1045-9. PubMed ID: 17592271
[TBL] [Abstract][Full Text] [Related]
15. Surgical management of low-stage nonseminomatous germ cell testicular cancer.
Stephenson AJ; Klein EA
BJU Int; 2009 Nov; 104(9 Pt B):1362-8. PubMed ID: 19840014
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical assessment of tumor proliferation and volume of embryonal carcinoma identify patients with clinical stage A nonseminomatous testicular germ cell tumor at low risk for occult metastasis.
Albers P; Miller GA; Orazi A; Ulbright TM; Albers J; Donohue JP; Foster RS
Cancer; 1995 Feb; 75(3):844-50. PubMed ID: 7828136
[TBL] [Abstract][Full Text] [Related]
17. Treatment and Outcome of Patients with Stage IS Testicular Cancer: A Retrospective Study from the Spanish Germ Cell Cancer Group.
Aparicio J; Sánchez-Muñoz A; Ochenduszko S; Gumà J; Fernández-Aramburo A; García Del Muro X; Quiroga V; Sastre J; Alonso-Gordoa T; Sagastibelza N; Maroto P; Gómez de Liaño A; Vázquez S; Diz P; Durán I; Domenech M; Pinto A; Hernández A; González-Billalabeitia E; Terrasa J
J Urol; 2019 Oct; 202(4):742-747. PubMed ID: 31163007
[TBL] [Abstract][Full Text] [Related]
18. Outcome of patients with stage II and III nonseminomatous germ cell tumors: results of a single center.
Ataergin S; Ozet A; Arpaci F; Kilic S; Beyzadeoglu M; Komurcu S
Indian J Cancer; 2007; 44(1):6-11. PubMed ID: 17401218
[TBL] [Abstract][Full Text] [Related]
19. Does the histology of nodal metastasis predict systemic relapse after retroperitoneal lymph node dissection in pathological stage B1 germ cell tumors?
Beck SD; Foster RS; Bihrle R; Cheng L; Donohue JP
J Urol; 2005 Oct; 174(4 Pt 1):1287-90; discussion 1290. PubMed ID: 16145394
[TBL] [Abstract][Full Text] [Related]
20. The management of stage I nonseminomatous testicular germ cell tumors.
Pectasides D; Farmakis D; Pectasides M
Oncology; 2006; 71(3-4):151-8. PubMed ID: 17646698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
